Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy

Ademola K. Abiose, George A. Mansoor, Marybeth Barry, Richard Soucier, Chandra K. Nair, David Northrop Hager

Research output: Contribution to journalArticle

Abstract

We prospectively studied the effect of spironolactone, an aldosterone antagonist, on endothelial function in patients with advanced congestive heart failure (CHF) using the brachial artery reactivity method. Twenty patients optimized on conventional CHF therapy were treated with spironolactone, and brachial artery flow- mediated dilation was measured at baseline and at 4 and 8 weeks. Spironolactone improved endothelial function at 4 weeks, and sustained the improvement at 8 weeks, in patients with CHF on conventional medical therapy, presumably due to reversal of aldosterone impairment of endothelial nitric oxide activity.

Original languageEnglish (US)
Pages (from-to)1564-1566
Number of pages3
JournalThe American Journal of Cardiology
Volume93
Issue number12
DOIs
StatePublished - Jun 15 2004
Externally publishedYes

Fingerprint

Spironolactone
Brachial Artery
Heart Failure
Mineralocorticoid Receptor Antagonists
Aldosterone
Dilatation
Nitric Oxide
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. / Abiose, Ademola K.; Mansoor, George A.; Barry, Marybeth; Soucier, Richard; Nair, Chandra K.; Hager, David Northrop.

In: The American Journal of Cardiology, Vol. 93, No. 12, 15.06.2004, p. 1564-1566.

Research output: Contribution to journalArticle

Abiose, Ademola K. ; Mansoor, George A. ; Barry, Marybeth ; Soucier, Richard ; Nair, Chandra K. ; Hager, David Northrop. / Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. In: The American Journal of Cardiology. 2004 ; Vol. 93, No. 12. pp. 1564-1566.
@article{923c2c8b90ae4ace8043c1af672e27fc,
title = "Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy",
abstract = "We prospectively studied the effect of spironolactone, an aldosterone antagonist, on endothelial function in patients with advanced congestive heart failure (CHF) using the brachial artery reactivity method. Twenty patients optimized on conventional CHF therapy were treated with spironolactone, and brachial artery flow- mediated dilation was measured at baseline and at 4 and 8 weeks. Spironolactone improved endothelial function at 4 weeks, and sustained the improvement at 8 weeks, in patients with CHF on conventional medical therapy, presumably due to reversal of aldosterone impairment of endothelial nitric oxide activity.",
author = "Abiose, {Ademola K.} and Mansoor, {George A.} and Marybeth Barry and Richard Soucier and Nair, {Chandra K.} and Hager, {David Northrop}",
year = "2004",
month = "6",
day = "15",
doi = "10.1016/j.amjcard.2004.03.015",
language = "English (US)",
volume = "93",
pages = "1564--1566",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy

AU - Abiose, Ademola K.

AU - Mansoor, George A.

AU - Barry, Marybeth

AU - Soucier, Richard

AU - Nair, Chandra K.

AU - Hager, David Northrop

PY - 2004/6/15

Y1 - 2004/6/15

N2 - We prospectively studied the effect of spironolactone, an aldosterone antagonist, on endothelial function in patients with advanced congestive heart failure (CHF) using the brachial artery reactivity method. Twenty patients optimized on conventional CHF therapy were treated with spironolactone, and brachial artery flow- mediated dilation was measured at baseline and at 4 and 8 weeks. Spironolactone improved endothelial function at 4 weeks, and sustained the improvement at 8 weeks, in patients with CHF on conventional medical therapy, presumably due to reversal of aldosterone impairment of endothelial nitric oxide activity.

AB - We prospectively studied the effect of spironolactone, an aldosterone antagonist, on endothelial function in patients with advanced congestive heart failure (CHF) using the brachial artery reactivity method. Twenty patients optimized on conventional CHF therapy were treated with spironolactone, and brachial artery flow- mediated dilation was measured at baseline and at 4 and 8 weeks. Spironolactone improved endothelial function at 4 weeks, and sustained the improvement at 8 weeks, in patients with CHF on conventional medical therapy, presumably due to reversal of aldosterone impairment of endothelial nitric oxide activity.

UR - http://www.scopus.com/inward/record.url?scp=2942604308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942604308&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.03.015

DO - 10.1016/j.amjcard.2004.03.015

M3 - Article

C2 - 15194040

AN - SCOPUS:2942604308

VL - 93

SP - 1564

EP - 1566

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12

ER -